Atlas Trials

Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine

Clinical trial NCT01696123 · COMPLETED

Trial details

NCT number
NCT01696123
Sponsor
Shahid Beheshti University of Medical Sciences
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Alzheimer Disease
Start date
2011-01-01
Primary completion
2012-01-01
Enrollment
125

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.